TrialCancer research and treatment2017

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status.

Youngjoo Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.